Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carmot Therapeutics
Biotech
UPDATE: Roche muscles in on obesity market with $2.7B Carmot buy
The takeover will give Roche control of Carmot's clinical-phase injectable dual GLP-1/GIP receptor agonists and oral GLP-1 drug candidate.
Nick Paul Taylor
,
Gabrielle Masson
Dec 4, 2023 5:26am
Carmot files for IPO, heating up icy market waters
Nov 20, 2023 11:15am
Oncorus C-suite out the door—Chutes & Ladders
Jun 9, 2023 9:30am
Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist
Jan 17, 2018 10:40am
Amgen, Carmot ink backloaded $240M Parkinson’s pact
Dec 6, 2017 9:33am
Carmot nabs discovery deal with Genentech
Jul 6, 2016 10:51am